CDC Advisers Review Blood-Clotting Risk Associated With J&J’s Covid-19 Vaccine

U.S. vaccine advisers are meeting to consider whether to change recommendations on the use of Johnson & Johnson ’s Covid-19 vaccine because of the risk of a rare but serious blood-clotting condition.

The Advisory Committee on Immunization Practices is hearing updates from Centers for Disease Control and Prevention officials on reports of J&J vaccine recipients experiencing blood clots combined with low blood-platelet levels.